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Background
Clopidogrel is activated by CYP3A4 which also metabo-
lizes calcium channel blockers of the dihydropyridine
class. Due to the known CYP3A4 inhibition by calcium
channel blockers, we hypothesized that there might be a
drug-drug interaction between clopidogrel and dihydro-
pyridines in patients with coronary artery disease.
Materials and methods
Responsiveness to clopidogrel was assessed by the vasodi-
lator stimulated phosphoprotein (VASP) phosphoryla-
tion assay and aggregometry in 200 patients with
coronary artery disease undergoing percutaneous coro-
nary intervention.
Results
The platelet reactivity index (PRI in the VASP assay, nor-
mal range 69–100%) was higher in patients on both
clopidogrel and calcium channel blockers (61%) as com-
pared to patients on clopidogrel without calcium channel
blockers (48%). The absolute difference was 13%
(95%CI: 6–20%; p = 0.001) and the relative difference
approached 21%. A reduced effect of clopidogrel (PRI
>69%) was seen in 40% of patients with concomitant cal-
cium channel blocker treatment compared to 20% with-
out (χ2-test: p = 0.008). Intake of calcium channel blocker
remained an independent predictor of reduced platelet
inhibition by clopidogrel after adjustment for cardiovas-
cular risk factors. This corresponded to an increased plate-
let aggregation of similar magnitude (p < 0.05) and was
associated with adverse clinical outcome. In vitro incuba-
tion with calcium channel blockers (nimodipine, vera-
pamil, amlodipine and diltiazem) did not alter the PRI or
the ADP-induced platelet aggregation of patients on clopi-
dogrel. This indicates that the negative effect occurs in vivo,
conceivably at the level of the CYP3A4 cytochrome.
Conclusion
Co-administration of calcium channel blockers is associ-
ated with a decreased platelet inhibition by clopidogrel.
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